Kenvue (KVUE) Falls to New All-Time Low as Trump Hits Tylenol

We recently published 10 Stocks Lost This Big While Wall Street Celebrates. Kenvue Inc. (NYSE:KVUE) is one of the worst performers on Monday.

Shares of Kenvue Inc. (NYSE:KVUE) fell to a new all-time low after President Donald Trump linked autism to the use of Tylenol during pregnancy.

During the session, shares of the company dropped to its lowest 52-week price of $16.89 before ending the day down by 7.47 percent at $16.97 apiece.

In an extraordinary conference at the White House, Trump delivered advice to pregnant women and parents of young children, telling them not to take over-the-counter painkillers.

“I want to say it like it is, don’t take Tylenol. Don’t take it,” Trump said. “Fight like hell not to take it. There may be a point where you have to, and that you’ll have to work out with yourself, so don’t take Tylenol.”

Trump, who was seated beside anti-vaccine Health Secretary Robert F. Kennedy Jr., called for the reexamination of a link between vaccines and autism.

Kenvue Inc. (NYSE:KVUE), maker of Tylenol, issued a statement to defend its product shortly after Trump’s statement.

“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” Kenvue Inc. (NYSE:KVUE) said.

While we acknowledge the potential of KVUE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.